Charles River Laboratories International Inc.

CRL

$200.68

-14.5% last 12 months

Ken Fisher Holding value: $48.6 Million Joel Greenblatt Holding value: $3.22 Million Ken Griffin Holding value: $1.46 Million Polen Capital Holding value: $1.1 Million Ray Dalio Holding value: $639 Thousand Steven Cohen Holding value: $0 Gabe Plotkin Holding value: $0 Jeremy Grantham Holding value: $0 Jim Simons Holding value: $0 Mario Gabelli Holding value: $0 Tom Russo Holding value: $0 George Soros Holding value: $0

Market Cap

$10 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$181.22 - $262.00

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

20.25x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $10 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $12.6 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -14.5%
52-Week High Highest share price in the last 52 weeks. $262.00
52-Week Low Lowest share price in the last 52 weeks. $181.22
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.1
Outstanding Shares The number of shares the company has issued and are held by stockholders. 51.2 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 586 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 20.25
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 186.3
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $9.67
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 2.54
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 3.34
Enterprise Value to Revenue Enterprise value divided by revenue 3.08
Enterprise Value to EBIT Enterprise Value divided by EBIT 18.79
Total Debt to Enterprise Value Total debt divided by enterprise value 0.22
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.88

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $4.09 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $1.5 Billion
EBIT Earnings before tax and interest payments. $670 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $496 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 12.13%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +10.9%
Return on Equity Equity divided by market cap. 15.97%
Return on Assets Indicates a company's profitability in relation to its total assets. 6.45%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 9.97%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2022 Q4 2022 Q1 2023 Q2 2023

About Charles River Laboratories International Inc.

CEO: James Foster

Employees: 17,000

Industry: Research and Development in Biotechnology

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Similar stocks

Repligen Corp.
Repligen Corp.
Scynexis Inc
Scynexis Inc
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.

News

CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Charles River Laboratories International, Inc. - CRL

CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Charles River Laboratories International, Inc. - CRL

NEW ORLEANS, May 26, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind ...

PR Newswire PR Newswire, 7 days ago
LAWSUITS FILED AGAINST MPW, VIRT and CRL - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

LAWSUITS FILED AGAINST MPW, VIRT and CRL - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of t...

Accesswire Accesswire, 9 days ago
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Charles River Laboratories International, Inc. - CRL

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Charles River Laboratories International, Inc. - CRL

CEDARHURST, N.Y., May 24, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Charles River...

GlobeNewswire GlobeNewswire, 9 days ago
CHARLES RIVER LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Charles River Laboratories International, Inc. - CRL

CHARLES RIVER LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Charles River Laboratories International, Inc. - CRL

NEW ORLEANS, May 23, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 18, 2023 to fi...

GlobeNewswire GlobeNewswire, 10 days ago
Never miss a trade
To improve your user experience we use cookies.